Explore
Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Read More
Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results
Immunome Submits NDA for Varegacestat and Reports Financial Results
Read More
Trendline
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
Read More
Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Read More
Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Read More
Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Read More
Trendline
INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development
INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development
Read More
Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Read More
Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Read More
Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Read More
Trendline
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Read More
Trendline
Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials
Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials
Read More
